Valeant CEO J. Michael Pearson is plenty familiar with the pharma M&A space; after all, he's made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happening left and right in the sector, some of pharma's recent acquisitions "are not going to work."
A group of Chinese biotech heavyweights are banding together to buy Ambrx, R&D partner to the likes of Bristol-Myers Squibb and Merck, in hopes of making the company a go-to collaborator in their native country.
Earlier this week, Endo inked a pact to nab Par Pharmaceutical for $8 billion. But to do that, it'll need a loan, and it's agreed to a $9.275 billion loan package to back the acquisition.
Get ready for more of a squeeze on drugs used by seniors. CVS Health agreed to pay $12.7 billion for the pharmacy services company Omnicare, which specializes in assisted living and long-term care facilities.
India's Cadila Healthcare has emerged as the leading horse in a race to acquire the generic sterile injectables business of Claris Lifescience, and it's reportedly putting the finishing touches on a deal.
South Africa-based Aspen Pharmacare is looking to expand its global footprint, and the company is selling off two of its pharma portfolios to India's Strides Arcolab for a combined $301 million to lighten its load and put extra cash in the pot as it gears up for international growth.
Pfizer needs to make a deal--or several. It's obviously amenable to another megamerger, given that it tried to snap up AstraZeneca for more than $100 billion last year. So why not GlaxoSmithKline?
Valeant's next pickup could come from the Middle East, where it's reportedly in deal talks with one of Egypt's largest drugmakers, Amoun.
The latest market chatter is that Pfizer, rebuffed in its quest to acquire AstraZeneca last year, is taking a hard look at GlaxoSmithKline, and one analyst says it might be a good idea.
Chinese bidders are emerging in the long-sought sale of Bayer's diabetes device business, as the German giant seeks to focus on its core pharmaceutical interests.